Sports Medicine and Health Science
July 1, 2026
David Wing, Bart Roelands, Abraham Z. Snyder et al.
Neuroimaging studies show that the functional connectivity of the brain changes with age. Resting state functional connectivity (rsFC) in the brain appears to decrease with aging in key networks associated with higher order thinking and effective emotional regulation. Interventions that potentially preserversFC in the brain include 1) physical activity and 2) contemplative practice commonly...
Psychopharmacology
October 27, 2025
David A Bender, Sandeep M. Nayak, Joshua S. Siegel et al.
Psychedelic treatments are considered to involve unique treatment challenges relative to other psychiatric interventions, though these are typically not explored in detail within clinical trial reports. To determine the types of challenges that providers encounter while administering psychedelic drugs in research settings and to assess provider opinions on safeguards that may be pursued to...
Scientific Data
June 5, 2025
Subha Subramanian, Travis Rick Renau, Demetrius Perry et al.
4 citations
Psilocybin (PSIL) is a psychedelic drug and a promising experimental therapeutic for many psychiatric conditions. Precision functional mapping (PFM) combines densely repeated resting state fMRI sampling and individual-specific network mapping to improve signal-to-noise ratio (SNR) and effect size in brain imaging research. We present a randomized cross-over study in which PFM was used to...
American Journal of Psychotherapy
May 6, 2025
David A Bender, Sandeep M. Nayak, Joshua S. Siegel et al.
7 citations
Psychedelic therapies are promising new treatment options in psychiatry. Including the use of physical touch as part of treatment is an area of debate. This study aimed to characterize the viewpoints of practitioners on the use of touch in psychedelic therapy. An anonymous survey was distributed via e-mail to the contacts listed on ClinicalTrials.gov for trials of psilocybin and lysergic acid...
Nat Hum Behav
February 24, 2025
Ginger E. Nicol, Danielle R Adams, Eric J Lenze et al.
4 citations
There is a push to shrink the anticipated 17-year research-to-practice gap for psychedelic-assisted therapy (PAT), offering precarious hope to those with disabling mental health conditions. However, numerous questions regarding how PAT works, how well it works, for whom and in what context remain. Substantial changes to current systems of care, including regulatory approvals, clinical training...
The Journal of Clinical Psychiatry
February 5, 2025
David A Bender, Sandeep M. Nayak, Joshua S. Siegel et al.
3 citations
Objective: To assess the viewpoints of psychedelic practitioners in research settings on approaches to psychological support for psychedelic treatments. Methods: An anonymous survey was distributed via email to contacts listed on ClinicalTrials.gov for clinical trials of psilocybin and LSD, personal contacts of authors, and through snowball sampling. The survey included Likert type, multiple...
Nature
August 1, 2024
Joshua S. Siegel, Subha Subramanian, Demetrius Perry et al.
241 citations
A single dose of psilocybin, a psychedelic that acutely causes distortions of space-time perception and ego dissolution, produces rapid and persistent therapeutic effects in human clinical trials1-4. In animal models, psilocybin induces neuroplasticity in cortex and hippocampus5-8. It remains unclear how human brain network changes relate to subjective and lasting effects of psychedelics. Here...
International Journal of Geriatric Psychiatry
July 1, 2023
Benjamin Vanderschelden, M. A. Gebara, H. Oughli et al.
13 citations
To examine whether psychological well‐being, sleep, and suicidality improved with treatment with intravenous (IV) ketamine for late‐life treatment‐resistant depression (TRD).
Missouri medicine
2023
Joshua S. Siegel, Craig S Pearson, Eric J Lenze
592 citations
The 21st century has brought novel therapies and new therapeutic targets for major depressive disorder (MDD). Until recently all antidepressant medications targeted monoamines-serotonin, norepinephrine, and dopamine- and their regulatory systems. But growing evidence has suggested that individuals who fail to respond to a monoaminergic treatment are likely to fail to respond to other...
JAMA
December 13, 2022
Eric J Lenze, Michelle Voegtle, J Philip Miller et al.
Episodic memory and executive function are essential aspects of cognitive functioning that decline with aging. This decline may be ameliorable with lifestyle interventions. To determine whether mindfulness-based stress reduction (MBSR), exercise, or a combination of both improve cognitive function in older adults. This 2 × 2 factorial randomized clinical trial was conducted at 2 US sites...
The American journal of geriatric psychiatry
December 1, 2022
H. Oughli, M. A. Gebara, A. Ciarleglio et al.
33 citations
Objective: Evidence-based treatment options for late-life treatment-resistant depression (TRD) are limited. Ketamine is a promising treatment for TRD; however, there is a paucity of data on its safety and efficacy in older adults. Methods: In this pilot clinical trial, 25 adults aged ≥60 years with TRD received IV ketamine openly twice a week for 4 weeks; partial responders at the end of this...
Journal of Neurological Sciences
2022
Subha Subramanian, S. Haroutounian, Ben J Palanca et al.
58 citations
Ketamine is an anesthetic drug which is now used to treat chronic pain conditions and psychiatric disorders, especially depression. It is an N-methyl-D-aspartate (NMDA) receptor antagonist with additional effects on α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, opioid receptors, and monoaminergic...
Mindfulness
October 5, 2021
Heather J. Brooks, H. Oughli, Lojine Y. Kamel et al.
Individuals with subjective memory complaints and symptoms of depression and/or anxiety are at high risk for further cognitive decline, and possible progression to dementia. Low-burden interventions to help slow or prevent cognitive decline in this high-risk group are needed. The objective of this study is to assess the feasibility of combining Mindfulness-Based Stress Reduction (MBSR) with...
Psychopharmacology
January 22, 2021
J. Siegel, Ben J Palanca, Beau M Ances et al.
53 citations
Ketamine produces a rapid antidepressant response in over 50% of adults with treatment-resistant depression. A long infusion of ketamine may provide durable remission of depressive symptoms, but the safety, efficacy, and neurobiological correlates are unknown. In this open-label, proof-of-principle study, adults with treatment-resistant depression (N = 23) underwent a 96-h infusion of...
Frontiers in Psychiatry
May 14, 2018
Ben J Palanca, Hannah R. Maybrier, Angela M. Mickle et al.
16 citations
Electroconvulsive therapy (ECT) employs the elective induction of generalizes seizures as a potent treatment for severe psychiatric illness. As such, ECT provides an opportunity to rigorously study the recovery of consciousness, reconstitution of cognition, and electroencephalographic (EEG) activity following seizures. Fifteen patients with major depressive disorder refractory to pharmacologic...